BioNano Genomics, Inc. Forecast, price target & analysts
BioNano Genomics, Inc. Target price 2026 - Analyst rating & recommendation
BioNano Genomics, Inc. Classifications & Recommendation
BioNano Genomics, Inc. Price Target
| Target Price | $5.10 |
| Price | $1.48 |
| Potential |
244.60%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target BioNano Genomics, Inc. 2027 .
The average BioNano Genomics, Inc. target price is $5.10.
This is
244.60%
register free of charge
$6.30
325.68%
register free of charge
$4.04
172.97%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend BioNano Genomics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioNano Genomics, Inc. stock has an average upside potential 2027 of
244.60%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 28.51 | 32.78 |
| 7.37% | 14.98% | |
| EBITDA Margin | -98.00% | -31.12% |
| 56.71% | 68.25% | |
| Net Margin | -92.60% | -84.67% |
| 74.56% | 8.56% |
4 Analysts have issued a sales forecast BioNano Genomics, Inc. 2026 . The average BioNano Genomics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an BioNano Genomics, Inc. EBITDA forecast 2026. The average BioNano Genomics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2025 | $-27.9m | 59.90% |
|---|---|---|
| 2026 |
$-10.2m
63.49%
unlock
|
|
EBITDA Margin
| 2025 | -98.00% | 56.71% |
|---|---|---|
| 2026 |
-31.12%
68.25%
unlock
|
|
4 BioNano Genomics, Inc. Analysts have issued a net profit forecast 2026. The average BioNano Genomics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.85 | -2.36 |
| 94.50% | 51.34% | |
| P/E | negative | |
| EV/Sales | 0.34 |
4 Analysts have issued a BioNano Genomics, Inc. forecast for earnings per share. The average BioNano Genomics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioNano Genomics, Inc....
Current BioNano Genomics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 13 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 24 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 18 2025 |
| Maxim Group |
Locked
➜
Locked
|
Locked | May 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| Ladenburg Thalmann |
Locked
➜
Locked
|
Locked | Nov 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 13 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 24 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 18 2025 |
|
Locked
Maxim Group:
Locked
➜
Locked
|
May 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 09 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
Ladenburg Thalmann:
Locked
➜
Locked
|
Nov 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
